In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.

@article{Allemandi1994InvitroAO,
  title={In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus.},
  author={Daniel Alberto Allemandi and Fabiana L. Alovero and Rub{\'e}n Hilario Manzo},
  journal={The Journal of antimicrobial chemotherapy},
  year={1994},
  volume={34 2},
  pages={
          261-5
        }
}
Two new quinolones, NSFQ-104 and NSFQ-105, derivatives of ciprofloxacin and norfloxacin with a 4-(4-aminophenylsulphonyl)-1-piperazinyl at position 7 showed better in-vitro activity against strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus than ciprofloxacin or norfloxacin. Their in-vitro activity was enhanced at pH 5.5. 
Activity of Newer Fluoroquinolones In Vitro Against Gram-Positive Bacteria
TLDR
Enhanced potency of several newer quinolones may result in a favourable pharmacodynamic profile leading to improved outcomes against Gram-positive infections and possibly to the delayed or diminished emergence of resistance to these agents. Expand
Comparative study of new benzenesulphonamide fluoroquinolones structurally related to ciprofloxacin against selected ciprofloxacin-susceptible and -resistant Gram-positive cocci.
TLDR
A high degree of correlation was found between the MICs of the new compounds and ciprofloxacin for Staphylococcus spp. Expand
Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids.
Oxazolidinone-quinolone hybrids that combine the pharmacophores of a quinolone and an oxazolidinone were synthesised and shown to be active against a variety of resistant and susceptibleExpand
Mode of Action of Sulfanilyl Fluoroquinolones
TLDR
Results indicate that NSFQs having only one ionizable group could exhibit more favorable kinetics of access to the bacterial cell than zwitterionic fluoroquinolones. Expand
Novelties in the field of anti-infective compounds in 1999.
  • A. Bryskier
  • Biology, Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
In 1999 the number of new compounds reported in the anti-infective field decreased significantly in comparison with previous years, especially for antifungals. The reported new compounds are mainlyExpand
Activity In Vitro of the Quinolones
TLDR
The fluoroquinolones continue to provide excellent in vitro activity against most commonly encountered gram-negative bacteria, however, in certain areas of the world or in specific institutional settings, significant numbers of Escherichia coli or Klebsiella spp. Expand
In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex.
TLDR
As pharmacodynamic properties of CIPX are not drastically affected by being complexed with aluminium, the increased aqueous compatibility of the complex remains as the main formulation factor for liquid dosage forms. Expand
Synthesis, Antibacterial Evaluation and QSAR of α-Substituted-N4-Acetamides of Ciprofloxacin and Norfloxacin
TLDR
QSAR revealed that while polarity is the major contributing factor in the potency against Staphylococcus aureus, it is balanced by lipophilicity and electron density around the acetamide group. Expand
Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
TLDR
The bactericidal mode of action of ozenoxacin and control drugs was consistently maintained (MBC/MIC ratios ≤4) in spite of variations of their activity under different test conditions. Expand
Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase
TLDR
Data show unequivocally that the C-7 substituent determines not only the potency but also the target preference of fluoroquinolones, which supports one key postulate of the Shen model of quinolone action. Expand
...
1
2
...